Glucocorticoid-Induced Osteoporosis (GIOP)

Indian J Orthop. 2023 Nov 29;57(Suppl 1):181-191. doi: 10.1007/s43465-023-01037-8. eCollection 2023 Dec.

Abstract

Use of glucocorticoid in various diseases including rheumatology and respiratory diseases is on the rise because of its prompt beneficial effects. This culminates in osteoporosis and fragility fractures. Judicious use of glucocorticoid hence calls for attention with regard to the dose schedule, route of administration and accompanying enhancing factors. Institution of proper therapeutic management as per WHO risk stratification with anabolic and/or resorptive drugs like bisphosphonates, teriparatide or denosumab is necessary to prevent the eventuality of fragility fractures. Even otherwise, knowledge of glucocorticoid, its metabolism, various dose schedules, adverse effects are areas worth discussing.

Keywords: Adverse effects; Deflazacort; Fragility fracture; GIOP; Glucocorticoid; Osteoporosis; Prednisolone.

Publication types

  • Review